Software development company

Apticraft Systems is a fast developing bioinformatics web development company who announced the successful achievement of the PrimerPlex project prized to it by PREMIER Biosoft International, USA. Apticraft spoke in front of the press that the project has been finished in evidence in one year time.

This was started by them that the first of its type project which they had handled. The xMAP® technology is definitely changing the method of flow cytometry research is performed. The xMAP® web development technology merges the ability of stream cytometry with the correctness of microsphere based detection as spoken by Shonali Paul, Director, Apticraft Systems.The Research labs of Apticraft Systems learning single nucleotide polymorphisms of web development can at present complete composite assay design in minutes. The Articraft System web development will save a lot of time while developing any polymorphism project. 

The software interface design showed a specific challenge for concurrently addressing two dissimilar assays. It also concerned superior computations to screen the effects for cross reactivity. Apticraft was able to solve this through extensive research compromising the revise of technology contents, articles, communication with contemporary experts and rigorous testing to perform easily to have satisfied web development from the client side before delivery of the project. They told that they know it would be tough, 100 assays concurrently typically are. But our scientists were in touch with technology experts regularly web development to have better option for this. The program went through web development several rounds of optimization to output the best oligos,” commented Shonali Paul. 

“PrimerPlex was designed targeting the SNP genotyping market. Apticraft Systems did an admirable job in creating user-friendly interface capable of handling two assays simultaneously and designing a complex algorithm. We will web development certainly keep Apticraft in mind for future projects.” commented Kay Brown, President, and PREMIER Biosoft International